Alice Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alice Wang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ayman Al-Hendy
Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA
1 shared publication Bruce R. Carr
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX
1 shared publicationCharlotte D. Owens
Department of Obstetrics and Gynecology, AbbVie Inc, North Chicago, IL
1 shared publication- David F. Archer
Eastern Virginia Medical School, Norfolk, VA
1 shared publication - Elizabeth A. Stewart
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, USA
1 shared publication Elizabeth E. Puscheck
Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI
1 shared publication
Latest Publications
- Open Access
- 20 July 2020
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 224 (1) , 72.e1-72.e50
Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids
- 20 July 2020
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 224 (1) , 72.e1-72.e50
Open AccessPredictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids
- Open Access
- 19 June 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0199122
Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts
The prostate-specific antigen (PSA) based prostate cancer (PC) screening is currently being debated. The current assessment is to understand the variability of detecting high-risk PC in a NZ cohort in comparison to a US cohort with better PSA screening facilities. Aldo-keto reductase 1C3 (AKR1C3) is known for multiple functions with a potential to regulate subsequent PSA levels. Therefore, we wish to understand the influence of tobacco smoking and the AKR1C3 rs12529 gene polymorphism in this variability. NZ cohort (n = 376) consisted of 94% Caucasians while the US cohort consisted of African Americans (AA), n = 202, and European Americans (EA), n = 232. PSA level, PC grade and stage at diagnosis were collected from hospital databases for assigning high-risk PC status. Tobacco smoking status and the AKR1C3 rs12529 SNP genotype were considered as confounding variables. Variation of the cumulative % high-risk PC (outcome variable) with increasing PSA intervals (exposure factor) was compared between the cohorts using the Kolmogorov-Smirnov test. Comparisons were carried out with and without stratifications made using confounding variables. NZ cohort has been diagnosed at a significantly higher mean age (66.67± (8.08) y) compared to both AA (62.65±8.17y) and EA (64.83+8.56y); median PSA (NZ 8.90ng/ml compared to AA 6.86ng/ml and EA 5.80ng/ml); and Gleason sum (NZ (7) compared EA (6)) (p6 - AKR1C3 rs12529 G alleles making them a group that requires increased PSA screening attention.
- 19 June 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0199122
Open AccessInfluence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts
The prostate-specific antigen (PSA) based prostate cancer (PC) screening is currently being debated. The current assessment is to understand the variability of detecting high-risk PC in a NZ cohort in comparison to a US cohort with better PSA screening facilities. Aldo-keto reductase 1C3 (AKR1C3) is known for multiple functions with a potential to regulate subsequent PSA levels. Therefore, we wish to understand the influence of tobacco smoking and the AKR1C3 rs12529 gene polymorphism in this variability. NZ cohort (n = 376) consisted of 94% Caucasians while the US cohort consisted of African Americans (AA), n = 202, and European Americans (EA), n = 232. PSA level, PC grade and stage at diagnosis were collected from hospital databases for assigning high-risk PC status. Tobacco smoking status and the AKR1C3 rs12529 SNP genotype were considered as confounding variables. Variation of the cumulative % high-risk PC (outcome variable) with increasing PSA intervals (exposure factor) was compared between the cohorts using the Kolmogorov-Smirnov test. Comparisons were carried out with and without stratifications made using confounding variables. NZ cohort has been diagnosed at a significantly higher mean age (66.67± (8.08) y) compared to both AA (62.65±8.17y) and EA (64.83+8.56y); median PSA (NZ 8.90ng/ml compared to AA 6.86ng/ml and EA 5.80ng/ml); and Gleason sum (NZ (7) compared EA (6)) (p6 - AKR1C3 rs12529 G alleles making them a group that requires increased PSA screening attention.